TABLE 1.
Clinical and demographic features of patients with severe eosinophilic asthma on commencing mepolizumab (V1)
| Patients | 101 |
| Age (years) | 54.4±11.9 |
| Female | 58 (57.4) |
| Smoking status | |
| Never-smoker | 60 (61.9) |
| Ex-smoker | 35 (36.1) |
| Current smoker | 2 (2.1) |
| BMI (kg·m−2) | 30.5±5.8 |
| Age at onset of asthma (years) | 30 (14–40) |
| Atopic disease | 47 (48.5) |
| Glucocorticoid rescue courses per 12 months | 5 (2–7) |
| Cumulative prednisolone dose (mg) per 12 months | 4280 (3085–5475) |
| ED visits per 12 months | 120/39 patients |
| Hospital admissions per 12 months | 60/29 patients |
| Ever been ventilated | 14 (13.9) |
| FEV1 % predicted # | 68.9±19.0 |
| FEV1/FVC % | 61.9±14.6 |
| FeNO (ppb) | 35 (20.3–56.8) |
| Blood eosinophil (cells·µL−1) | 280 (100–600) |
| Highest blood eosinophils (cells·µL−1) in medical record | 860 (600–1300) |
| IgE (kU·L−1) | 117.5 (42.3–351.3) |
| Bone density T score (hip) | −0.40±1.1 |
| Bone density T score (spine) | −0.72±1.1 |
| Daily prednisolone | 83 (82.2) |
| Daily prednisolone dose (mg) (n=83) | 10 (10–15) |
| ICS daily dose (BDP µg equivalent) | 2000 (2000–2000) |
| Long-acting β-agonist | 101 (100) |
| Long-acting muscarinic antagonist | 35 (36.5) |
| Leukotriene receptor antagonists | 51 (51) |
| Theophylline | 38 (38.4) |
| Nebulised bronchodilators | 33 (34.4) |
| Maintenance macrolide | 7 (7) |
| ACQ5 | 2.6±1.3 |
| Mini-AQLQ | 3.6±1.4 |
| SGRQ | 55.8±20.9 |
| EuroQoL-5D5L index | 0.63 (0.4–0.8) |
| EuroQoL-5D5L health scale | 65 (50–75) |
| HADS depression | 6 (3–11) |
| HADS anxiety | 8 (5–14) |
Data are presented as n, mean±sd, n (%) and median (interquartile range). Further descriptive statistics for these variables can be found in supplementary table E1. BMI: body mass index; ED: emergency department; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; FeNO: exhaled nitric oxide fraction; ICS: inhaled corticosteroid; BDP: beclomethasone dipropionate; ACQ: Asthma Control Questionnaire; AQLQ: Asthma Quality of Life Questionnaire; SGRQ: St George's Respiratory Questionnaire; HADS: Hospital Anxiety and Depression Scale. #: using Global Lung Initiative 2012 predictive values.